RuiXin Medical Ranked Among the 2026 Future Healthcare 100, Recognized as a Top 100 Innovative Medical Device & Intelligent Manufacturing Company

May 23, 2026 18:06 CST Updated 18:06

RaysightMed

Medical Imaging Product Developer

On May 21, 2026, the "2026 Future Healthcare and Pharmaceutical Top 100 Conference," hosted by Vbdata, successfully concluded in Shanghai. During the conference,The 10th"2026 Future Healthcare 100 Strong" series list officially announced, RaysightMed successfully selected for "Innovative Devices and Intelligent Manufacturing TOP100".

The "Future Healthcare 100 Strong" list was jointly initiated by VB100 and others in 2015. It is the first authoritative selection in China for non-listed healthcare companies. RaysightMed's inclusion on the list marks the industry's high recognition of its technological innovation, commercial implementation, and overall strength in the AI + cardiovascular precision diagnosis and treatment field.

TOP100 List of Innovative Medical Devices and Intelligent Manufacturing 2026 (Top 25 shown in the figure)

Hardcore Strength, Showcasing the Benchmark Power of Cardiovascular AI Diagnosis and Treatment

This honorary accolade represents the industry's high recognition of RaysightMed's deep dedication to the field of cardiovascular functional diagnostics. Since its establishment in 2017, RaysightMed has consistently adhered to the mission of "Using intelligent technology to safeguard the longer rhythm of life," focusing on AI for cardiocerebrovascular applications and surgical robotics for precision diagnosis and treatment. The company has built a fully closed-loop intelligent diagnosis and treatment platform covering screening, diagnosis, surgery, and post-operative management.

Relying on cutting-edge technologies such as artificial intelligence, computational fluid dynamics, intracardiac ultrasound imaging, and robotics, the company has developed several milestone products:

✅ RaysightMed's non-invasive CT-FFR product, RuiXin Score, based on AI+CFD technology, has obtained NMPA Class III Innovative Medical Device Certification and EU CE certification. It provides non-invasive and precise assessment of coronary ischemia and has served a large number of patients with coronary heart disease.

✅ One-stop Coronary Functional Assessment SystemAngioQFA, Synchronous Achievement of Macro FFR + Micro IMR Precision Measurement, assisting in intraoperative decision-making;

✅ Fully automatic AI vascular interventional surgery robot, breaking the monopoly of high-end interventional device imports, accelerating the substitution of domestically produced devices and overseas expansion;

✅ ICE Intracardiac Echocardiography System, relying on cutting-edge ultrasound imaging and AI intelligent analysis technology, accurately presents the anatomical structure and functional status within the heart chambers, providing real-time visualization guidance for interventional procedures such as arrhythmias and structural heart diseases.

Deepening the Track, Practicing for the Long Haul. Currently, RaysightMed has obtained 13 NMPA registrations, 1 EU CE certification, accumulated over 200 patents, and cooperated with more than 800 clinical hospitals. During its development, the company has received investments from top capital institutions such as CASSTAR, HuaChuang, Matrix Partners, and Tencent, steadily growing into a leading benchmark enterprise in China's cardiovascular AI diagnosis and treatment field.

In the new industrial cycle of 2026, characterized by the deep integration of medical AI, the domestic substitution of high-end devices, and the parallel trend of globalization, RaysightMed's inclusion in the "Future Healthcare 100 Strong" Top 100 Innovative Devices list not only endorses the company’s technical barriers and commercial momentum but also reflects the trend of China's original innovative device enterprises moving towards the higher end of the global value chain. In the future, RaysightMed will continue to deepen its "AI + robotics" precision diagnosis and treatment platform for cardiovascular and cerebrovascular diseases, using intelligent technology to safeguard the rhythm of life for a longer duration.